Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Original publication

DOI

10.1093/cvr/cvab239

Type

Journal article

Journal

Cardiovasc Res

Publication Date

27/07/2021

Volume

117

Pages

e110 - e113

Keywords

Antithrombotic, Antiviral, COVID-19, Immunomodulation, Randomized trial, Aged, Anti-Inflammatory Agents, Antiviral Agents, COVID-19, Cardiovascular Diseases, Cause of Death, Female, Fibrinolytic Agents, Heart Disease Risk Factors, Humans, Male, Middle Aged, Research Design, Risk Assessment, Time Factors, Treatment Outcome